News

On September 25, 2023 we celebrated Heffter’s 30th birthday.  You can see the list of the 156 research projects that have received Heffter funding since then here.  As of 2020, Heffter-affiliated researchers accounted for 63% (17 of 27) of the top-cited articles on classic psychedelics. We...

Here is our annual report of our progress this past year and future plans. Heffter’s largest supported study was recently completed, “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.”...

August 30, 2022  Dear Dr. Greer,  It is my pleasure to thank you for the Heffter Research Institute’s recent gift of $138,405 to support Dr. Yvan Beaussant’s PATH study for patients receiving hospice care. Thanks to your ongoing support, the first PATH study participant has successfully completed...

First, there have been changes at Heffter since our last newsletter. Carey Turnbull has succeeded George Greer as President. George has retired as Medical Director and is now Board Chair. Dave Nichols is Vice-President, and all three make up the Heffter Executive Committee....

Dear Friends and Supporters,

The Heffter Research Institute is celebrating 25 years of progress this year, having been incorporated in 1993!  We are hearing from more and more scientists who are becoming interested in the therapeutic potential of psilocybin-assisted therapy, and 2018 has been an exciting year of expansion, with new projects starting and in development.

2018 is bringing new opportunities for Heffter's research mission.  As the FDA Phase 3 work on psilocybin-assisted therapy for depression proceeds at the Usona Institute, Heffter is moving forward with its agenda to support research to test psilocybin's healing potential for other conditions, such as addictions, eating disorders, and Alzheimer's disease. The work ahead is only possible because of the decades of work by scientists and supporters alike who are dedicated to psychedelic research and have been working together to bring a dream into reality.

heffter-logo

2016 has been a watershed year for the Heffter Research Institute and its programs! We believe that our work is contributing to what we hope will be a paradigm shift in the way that many psychiatric and addictive disorders are treated. We hope you enjoy reading about all of the great things we have accomplished this past year.

Johns Hopkins and NYU Studies of Psilocybin for Anxiety and Depression in Cancer Patients

Our big news is the publication of two Heffter-supported studies on psilocybin treatment of anxiety and depression in cancer patients at Johns Hopkins and NYU on December 1. You can access the free full-text articles by clicking on those links.

The story about these studies was widely covered by the media. For example, it was on the front page of the NY Times that day: A Dose of a Hallucinogen From a ‘Magic Mushroom,’ and Then Lasting Peace. An analysis of all the media reporting indicates that the studies were covered in at least 600 media outlets that collectively reach millions of readers and viewers.*

So psilocybin research is now virtually common knowledge. At the end of this letter is the latest list of weblinks to all the online stories we found that mention Heffter’s role in this research.

Heffter Research Institute is proud to have supported new psilocybin studies published December 1 in The Journal of Psychopharmacology reporting the effectiveness of using psilocybin to reduce depression, anxiety and existential distress in cancer patients. Below is a round-up of articles discussing the recent findings...